Pneumocystosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Pneumocystosis, also known as Pneumocystis jiroveci pneumonia (PJP, previously referred to as Pneumocystis carinii pneumonia [PCP]), is an opportunistic infection primarily seen in individuals with impaired immunity. The causative agent of pneumocystosis is the Pneumocystis organism, which is commonly found in the lungs of both healthy humans and other mammals. The organism responsible for human disease is Pneumocystis jirovecii, a ubiquitous parasite present worldwide. The majority of children have antibodies to Pneumocystis by age 3-4, indicating prior exposure to the organism. In immunocompetent individuals, P. jirovecii typically does not cause disease. Its symptoms are relatively non-specific and may include breathlessness, fever, and a nonproductive (dry) cough. These symptoms tend to develop over several weeks in individuals infected with HIV. Physical signs of pneumocystosis are also non-specific and may include increased respiratory and heart rates. Lung examination may reveal mild crackles and rhonchi in approximately 50% of patients. The diagnosis of pneumocystosis is typically based on the microscopic identification of P. jirovecii from bronchopulmonary (lung) secretions obtained through methods such as induced sputum, bronchoalveolar lavage, or lung biopsy. Among these methods, bronchoalveolar lavage is considered the most reliable diagnostic method. The treatment of choice for pneumocystosis is co-trimoxazole.
·
The incidence of pneumocystosis is estimated
to be 2.5 to 3.8 cases per 100,000 population in the USA. Approximately
two-thirds of cases occurred in males. Additionally, a significant proportion
of patients diagnosed with pneumocystosis (PCP) are 50-75 years old.
Thelansis’s “Pneumocystosis Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Pneumocystosis
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Pneumocystosis across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Pneumocystosis Market Forecast Patient-Based
Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with
sourcing, Market Event, and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden, pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment